These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 12410249)

  • 1. Value drivers in licensing deals.
    Arnold K; Coia A; Saywell S; Smith T; Minick S; Löffler A
    Nat Biotechnol; 2002 Nov; 20(11):1085-9. PubMed ID: 12410249
    [No Abstract]   [Full Text] [Related]  

  • 2. Value creation and sharing among universities, biotechnology and pharma.
    Edwards MG; Murray F; Yu R
    Nat Biotechnol; 2003 Jun; 21(6):618-24. PubMed ID: 12776145
    [No Abstract]   [Full Text] [Related]  

  • 3. In-licensing as a business model.
    Schafer DP
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE36-9. PubMed ID: 12089585
    [No Abstract]   [Full Text] [Related]  

  • 4. Licensing deals morph to acquisitions in seller's market.
    Moran N
    Nat Biotechnol; 2007 Jun; 25(6):609-10. PubMed ID: 17557085
    [No Abstract]   [Full Text] [Related]  

  • 5. Changing partners.
    Nat Biotechnol; 2002 Sep; 20(9):855. PubMed ID: 12205487
    [No Abstract]   [Full Text] [Related]  

  • 6. Deal-making trends in oncology.
    Moore K; Walker J
    Nat Rev Drug Discov; 2009 Aug; 8(8):604. PubMed ID: 19644466
    [No Abstract]   [Full Text] [Related]  

  • 7. The closure of Sugen.
    Levitzki A
    Nat Biotechnol; 2003 Sep; 21(9):969. PubMed ID: 12949548
    [No Abstract]   [Full Text] [Related]  

  • 8. Patent threat in emerging economies shifts to biotech.
    Jayaranam K
    Nat Biotechnol; 2008 May; 26(5):481-3. PubMed ID: 18464760
    [No Abstract]   [Full Text] [Related]  

  • 9. The economics of licensing contracts.
    Mason R; Savva N; Scholtes S
    Nat Biotechnol; 2008 Aug; 26(8):855-7. PubMed ID: 18700253
    [No Abstract]   [Full Text] [Related]  

  • 10. When times get tough.
    Jong S
    Nat Biotechnol; 2009 Mar; 27(3):226-8. PubMed ID: 19274868
    [No Abstract]   [Full Text] [Related]  

  • 11. Calculating the value & risk in licensing deals. 20-21 November 2002, Brussels, Belgium.
    Contrafouris Y
    IDrugs; 2003 Jan; 6(1):21-2. PubMed ID: 12838965
    [No Abstract]   [Full Text] [Related]  

  • 12. Public biotech 2008--the numbers.
    Huggett B; Hodgson J; Lähteenmäki R
    Nat Biotechnol; 2009 Aug; 27(8):710-21. PubMed ID: 19668175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survey reveals US university licensing up, startup formation down.
    Bouchie A
    Nat Biotechnol; 2005 Feb; 23(2):261-2. PubMed ID: 15724274
    [No Abstract]   [Full Text] [Related]  

  • 14. Syndication--value in numbers.
    Sanborn KT
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE54-6. PubMed ID: 12089590
    [No Abstract]   [Full Text] [Related]  

  • 15. Hidden in plain view.
    Jacobs T
    Nat Biotechnol; 2003 Jun; 21(6):603. PubMed ID: 12776141
    [No Abstract]   [Full Text] [Related]  

  • 16. Getting real about valuations in biotech.
    Villiger R; Bogdan B
    Nat Biotechnol; 2005 Apr; 23(4):423-8. PubMed ID: 15815665
    [No Abstract]   [Full Text] [Related]  

  • 17. Partnering challenges for startups.
    French JM
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE40-2. PubMed ID: 12089586
    [No Abstract]   [Full Text] [Related]  

  • 18. Biotechnology. Mixed reactions to merger.
    Gershon D
    Nature; 1990 Feb; 343(6260):681. PubMed ID: 2304541
    [No Abstract]   [Full Text] [Related]  

  • 19. Best-selling human medicines 2002-2004.
    Maggon K
    Drug Discov Today; 2005 Jun; 10(11):739-42. PubMed ID: 15922927
    [No Abstract]   [Full Text] [Related]  

  • 20. Reinventing the biotech manager.
    Li J; Halal WE
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE61-3. PubMed ID: 12089592
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.